Bortezomib Administered Subcutaneously Is Well Tolerated in Bortezomib-Based Combination Regimens Used in Patients with Multiple Myeloma

Publisher： Karger

E-ISSN： 1423-0232|85|4|223-227

ISSN： 0030-2414

Source： Oncology, Vol.85, Iss.4, 2013-09, pp. : 223-227

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

LDH is an adverse prognostic factor independent of ISS in transplant‐eligible myeloma patients receiving bortezomib‐based induction regimens

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 4, 2015-04 ,pp. : 330-335

John Wiley & Sons Inc

Access to resources Recommend Favorite

Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib‐based treatment regimens

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 1, 2015-07 ,pp. : 66-79

John Wiley & Sons Inc

Access to resources Recommend Favorite

Subcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 5, 2015-06 ,pp. : 754-756

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bortezomib‐based therapy combined with high cut‐off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 7, 2015-07 ,pp. : 647-652

John Wiley & Sons Inc

Access to resources Recommend Favorite

The effects of bortezomib on bone disease in patients with multiple myeloma

By  

CANCER, Vol. 120, Iss. 5, 2014-03 ,pp. : 618-623

John Wiley & Sons Inc

Access to resources Recommend Favorite